FRA:DMP • DE000A2GS5D8
We assign a fundamental rating of 5 out of 10 to DMP. DMP was compared to 55 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of DMP get a neutral evaluation. Nothing too spectacular is happening here. DMP has a decent growth rate and is not valued too expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.48% | ||
| ROE | 17.87% | ||
| ROIC | 7.26% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.7% | ||
| PM (TTM) | 10% | ||
| GM | 66.57% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.44 | ||
| Debt/FCF | 6.15 | ||
| Altman-Z | 2.22 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.2 | ||
| Quick Ratio | 1.04 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.14 | ||
| Fwd PE | 14.64 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.07 | ||
| EV/EBITDA | 9.41 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.47% |
FRA:DMP (2/13/2026, 5:28:06 PM)
36.85
-0.05 (-0.14%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.47% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.14 | ||
| Fwd PE | 14.64 | ||
| P/S | 1.71 | ||
| P/FCF | 12.07 | ||
| P/OCF | 9.61 | ||
| P/B | 3.06 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.41 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.48% | ||
| ROE | 17.87% | ||
| ROCE | 11.89% | ||
| ROIC | 7.26% | ||
| ROICexc | 7.91% | ||
| ROICexgc | 21.74% | ||
| OM | 18.7% | ||
| PM (TTM) | 10% | ||
| GM | 66.57% | ||
| FCFM | 14.17% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.44 | ||
| Debt/FCF | 6.15 | ||
| Debt/EBITDA | 3.09 | ||
| Cap/Depr | 49.31% | ||
| Cap/Sales | 3.63% | ||
| Interest Coverage | 4.01 | ||
| Cash Conversion | 68.3% | ||
| Profit Quality | 141.71% | ||
| Current Ratio | 2.2 | ||
| Quick Ratio | 1.04 | ||
| Altman-Z | 2.22 |
ChartMill assigns a fundamental rating of 5 / 10 to DMP.DE.
ChartMill assigns a valuation rating of 5 / 10 to DERMAPHARM HOLDING SE (DMP.DE). This can be considered as Fairly Valued.
DERMAPHARM HOLDING SE (DMP.DE) has a profitability rating of 4 / 10.
The Price/Earnings (PE) ratio for DERMAPHARM HOLDING SE (DMP.DE) is 17.14 and the Price/Book (PB) ratio is 3.06.
The Earnings per Share (EPS) of DERMAPHARM HOLDING SE (DMP.DE) is expected to grow by 11.31% in the next year.